View Financial Health3SBio 配当と自社株買い配当金 基準チェック /263SBio配当を支払う会社であり、現在の利回りは1.29%で、収益によって十分にカバーされています。主要情報1.3%配当利回り-8.5%バイバック利回り総株主利回り-7.2%将来の配当利回り1.7%配当成長15.2%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向6%最近の配当と自社株買いの更新お知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.すべての更新を表示Recent updatesお知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listingお知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.お知らせ • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.お知らせ • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024お知らせ • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.お知らせ • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023お知らせ • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.お知らせ • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.お知らせ • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.お知らせ • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.決済の安定と成長配当データの取得安定した配当: TRSB.Fは 10 年未満配当金を支払っており、この間、支払額は 変動性 が高かった。増加する配当: TRSB.Fの配当金は増加していますが、同社は8年間しか配当金を支払っていません。配当利回り対市場3SBio 配当利回り対市場TRSB.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (TRSB.F)1.3%市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Biotechs)2.4%アナリスト予想 (TRSB.F) (最長3年)1.7%注目すべき配当: TRSB.Fの配当金 ( 1.29% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) と比べると目立ったものではありません。高配当: TRSB.Fの配当金 ( 1.29% ) はUS市場の配当金支払者の上位 25% ( 4.27% ) と比較すると低いです。株主への利益配当収益カバレッジ: TRSB.F の配当性向 (6.4%) は低いため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: TRSB.Fは 現金配当性向 ( 5.9% ) が低いため、配当金の支払いはキャッシュフローによって完全にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:14終値2026/05/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋3SBio Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関Bo YuChina International Capital Corporation LimitedZhuhong ChenChina Merchants Securities (HK) Co., LtdShitong HanCitic Securities Co., Ltd.32 その他のアナリストを表示
お知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.
お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.
お知らせ • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.
お知らせ • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.
お知らせ • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055
お知らせ • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.
お知らせ • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.
お知らせ • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.
お知らせ • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025
お知らせ • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.
お知らせ • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.
お知らせ • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.
お知らせ • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023
お知らせ • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.
お知らせ • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.
お知らせ • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.
お知らせ • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.